Amended Current Report Filing (8-k/a)
January 19 2018 - 10:22AM
Edgar (US Regulatory)
U.S. SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
8-K/A
Current Report Pursuant to Section 13 or
15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
July 25,
2017
MEDICINE MAN TECHNOLOGIES, INC.
(Exact name of small business issuer as
specified in its charter)
|
Nevada
|
000-55450
|
46-5289499
|
|
(State or other jurisdiction of incorporation)
|
(Commission File Number)
|
(IRS Employer ID No.)
|
4880 Havana Street
Suite 201
Denver, Colorado 80239
(Address of principal executive offices)
(303) 371-0387
(Issuer’s Telephone Number)
___________________________________
(Former Address)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ☐
EXPLANATORY NOTE
This Amendment is being filed to
provide the information required by Item 9.01(a) of this Report, including independent audit of the financial statements of
Denver Consulting Group for the fiscal years ended December 31, 2016 and 2015 and notes thereto, along with unaudited interim
periods financial statements for the nine months ended September 30, 2017 and 2016, and pro forma consolidated financial
statements applicable to this transaction.
Item 9.01 Financial Statements and Exhibits
(a) Financial statements of businesses
acquired
Filed herewith and incorporated herein by reference are the financial statements of Denver Consulting Group for the Years ended December
31, 2016 and 2015, and for the Nine Months ended September 30, 2017 and 2016.
(b) Proforma Financial
Information
Filed herewith as Exhibit 99.3
and incorporated herein by reference are the combined unaudited pro forma financial statements of Medicine Man Technologies,
Inc. and Denver Consulting Group for the periods ended September 30, 2017 and December 31, 2016.
(d) Financial Statements and
Exhibits
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this amendment to its report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
|
MEDICINE MAN TECHNOLOGIES, INC.
|
|
|
(Registrant)
|
|
|
|
|
Dated: January 19, 2018
|
By:
|
/s/ Brett Roper
|
|
|
|
Brett Roper,
Chief Executive Officer
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Dated: January 19, 2018
|
By:
|
/s/ Jonathan Sandberg
|
|
|
|
Jonathan Sandberg,
Chief Financial Officer
|
Medicine Man Technologies (QX) (USOTC:SHWZ)
Historical Stock Chart
From Mar 2024 to Apr 2024
Medicine Man Technologies (QX) (USOTC:SHWZ)
Historical Stock Chart
From Apr 2023 to Apr 2024
